Scarica l'app Stockscreener
18.69
0.90%
-0.17
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché TNXP Giù?
Forum
Previsione
Frazionamento azionario
Tonix Pharmaceuticals Holding Corp Borsa (TNXP) Ultime notizie
Tonix Pharmaceuticals (TNXP) Secures Global Rights for Promising Pain Treatment - GuruFocus
Tonix Pharmaceuticals Licenses Non-Opioid Pain Medicine Candidate From Rutgers University - marketscreener.com
Tonix Pharma Secures Rights to TNX-4900 for Pain Management - TipRanks
Tonix Pharmaceuticals licenses worldwide rights to non-opioid pain drug - Investing.com
Tonix Pharmaceuticals Licenses TNX-4900 for Neuropathic Pain - TradingView — Track All Markets
Tonix (Nasdaq: TNXP) licenses TNX-4900 for chronic neuropathic pain from Rutgers - Stock Titan
(TNXP) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Equities Analysts Offer Predictions for TNXP FY2025 Earnings - MarketBeat
Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel Amid Key Commercialization Phase - citybuzz
Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel - citybiz
Tonix Pharma Appoints New General Counsel - TipRanks
TNXP: Tonix Now a Commercial Stage Company Following the Launch of Tonmya - Smartkarma
TNXP: Tonix Now a Commercial Stage Company Following the Launch of Tonmya™ - Yahoo Finance
TNXP Stock Today, 7 December 2025: Price, Latest News and 2026 Forecasts for Tonix Pharmaceuticals - ts2.tech
Tonix Pharmaceuticals (TNXP) Stock Today, December 4, 2025: Tonmya Launch, Buyback and $400M ATM Define a Volatile Biotech Story - ts2.tech
Is Tonix Pharmaceuticals Holding Corp. stock ready for breakout - Newser
Tonix receives FDA clearance to launch phase 2 trial for major depressive disorder - Proactive financial news
Is Tonix Pharmaceuticals Holding Corp. stock positioned well for digital economy2025 Buyback Activity & Stepwise Entry and Exit Trade Signals - Newser
Tonix reports positive results in TNX-1500 phase 1 trial - MSN
Tonix Pharmaceuticals (TNXP) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Will Tonix Pharmaceuticals Holding (NASDAQ:TNXP) Spend Its Cash Wisely? - Sahm
Aug Drivers: Why Tonix Pharmaceuticals Holding Corp. stock is trending among retail traders2025 Price Targets & Weekly Watchlist for Hot Stocks - moha.gov.vn
Why analysts remain bullish on Tonix Pharmaceuticals Holding Corp. stockCPI Data & Daily Volume Surge Signals - moha.gov.vn
Tonix Pharmaceuticals Stock Jumps Into Retail Spotlight After $25M Buyback Boost — Traders See ‘Blueprint For Rerating’ - MSN
What drives Tonix Pharmaceuticals Holding Corp stock priceTake Profit Strategies & Free Daily Top Stock Picks for All Investors - earlytimes.in
Tonix: Maintaining Buy Rating With Potential Tonmya Expansion Indications (NASDAQ:TNXP) - Seeking Alpha
Tonix Pharmaceuticals launches TONMYA, a first-in-class non-opioid Fibromyalgia therapy - Proactive financial news
FDA clears IND for Tonix’s depression treatment candidate By Investing.com - Investing.com Nigeria
Tonix Pharma’s IND Clearance Boosts MDD Treatment Efforts - TipRanks
Tonix Pharmaceuticals (TNXP) Secures FDA Clearance for Depressio - GuruFocus
Tonix To Initiate Phase 2 Trial Of TNX-102 SL For Major Depressive Disorder In Mid-2026 - RTTNews
Tonix Pharmaceuticals gets FDA clearance to develop TNX-102 for depression - Seeking Alpha
Tonix Pharmaceuticals announces FDA IND clearance for phase 2 study of TNX-102 SL - MarketScreener
Tonix Pharmaceuticals Announces FDA Ind Clearance For Phase 2 Study Of Tnx-102 Sl - TradingView
Pharmaceuticals Receives FDA Clearance to Proceed With Phase 2 Study of TNX-102 SL for Major Depressive Disorder - MarketScreener
Tonix Pharmaceuticals (TNXP) Advances with FDA IND Clearance for Depression Treatment - GuruFocus
FDA clears IND for Tonix’s depression treatment candidate - Investing.com India
Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder - The Manila Times
Tonix Pharmaceuticals to Advance TNX-102 SL into Pivotal Phase 2 Study for Major Depressive Disorder Following IND Clearance from FDA - Quiver Quantitative
Tonix Pharma (Nasdaq: TNXP) cleared to start Phase 2 HORIZON MDD study of TNX-102 SL - Stock Titan
Tonix Pharmaceuticals Announces FDA IND Clearance for Phase - GlobeNewswire
Tonix Pharmaceuticals Stock on November 23, 2025: Tonmya Launch, Bigger Buyback, and a $400M ATM Shape the TNXP Trade - ts2.tech
Tonix Pharmaceuticals increases stock offering capacity to $400 million By Investing.com - Investing.com Nigeria
Tonix Pharmaceuticals increases stock offering capacity to $400 million - Investing.com
Tonix Pharma Amends Sales Agreement to Raise Capital - TipRanks
Tonix Pharmaceuticals amends sales agreement with Alliance Global PartnersSEC filing - MarketScreener
Will Tonix Pharmaceuticals Holding Corp. stock split again soonEarnings Recap Report & Expert Approved Momentum Trade Ideas - newser.com
Can Tonix Pharmaceuticals Holding Corp. stock resist market sell offs2025 Big Picture & Long-Term Capital Growth Ideas - newser.com
How Tonix Pharmaceuticals Holding Corp. stock responds to policy changesCEO Change & Short-Term High Return Ideas - newser.com
Risk vs reward if holding onto Tonix Pharmaceuticals Holding Corp.Entry Point & Step-by-Step Swing Trade Plans - newser.com
Will Tonix Pharmaceuticals Holding Corp. stock deliver shareholder valueOil Prices & Consistent Growth Equity Picks - newser.com
Tonix Pharmaceuticals Holding Corp. (TNXP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
0.42%
0.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):